UNSPSC 51322904: Boxidine hydrochloride

This classification denotes an anti-lipidemic agent with the molecular formula C19H20F3NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3L4BF478JK, chemically known as pyrrolidine, 1-(2-((4-(trifluoromethyl)(1,1-biphenyl)-4-yl)oxy)ethyl)- but more generally known as boxidine hydrochloride, which bears US NIH Compound Identifier 31742. Most nations, for tariff and trade purposes, schedule boxidine hydrochloride under HS 29339990 and SITC 51577.

As of Q4 2014, BOXIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Boxidine hydrochloride bears US NLM identifiers UMLS ID C0959899 and NCI Concept Code C91026. SMILES: C1CC(CCC1C2CCC(CC2)OCCN3CCCC3)C(F)(F)F.CL.

UNSPSC 51322904 Boxidine hydrochloride, a Commodity code, does not reflect recent state and local procurement activity. The three most recent opportunities posted under or near this code involve Advanced Life Support Medications (Tampa Fire Rescue), a Texas Health and Human Services Commission direct-to-manufacturer pharmacy initiative, and a multistate cooperative purchasing agreement for generic pharmaceuticals and OTC products — none of which specifically name boxidine hydrochloride as a line item or core requirement. State and local governments soliciting under this code taxonomy are sourcing a broader class of emergency medications, prescription drugs, and generic pharmaceuticals through municipal fire departments, state health agencies, and cooperative purchasing vehicles rather than procuring boxidine hydrochloride as a standalone commodity.

The issuing bodies reflect a mix of municipal procurement (City of Tampa), state health agencies (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities in multiple states including Oregon). The Tampa Fire Rescue bid (IFB No. 26P00188, response deadline April 8, 2026, estimated contract value $40,000) exemplifies the municipal fire-service use case, while the Minnesota MMCAP RFP (due March 26, 2026) demonstrates multi-jurisdictional aggregate purchasing for generic pharmaceuticals through established wholesalers. Geographic activity appears concentrated in Texas, Minnesota, and Florida. Because boxidine hydrochloride does not appear in any of the recent solicitations and the code shows no direct procurement intent, pursue this code only if your firm manufactures or distributes boxidine as part of a broader emergency medication or generic pharmaceutical catalog that state or local emergency services or pharmacy benefit programs are actively sourcing.